EMA Authorised: Cimzia (certolizumab pegol) — UCB Pharma

View source ↗

Summary

The European Medicines Agency authorised Cimzia (certolizumab pegol) for treatment of rheumatoid arthritis and other inflammatory diseases, including psoriatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Crohn Disease
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid. MAH: UCB Pharma. Decision date: 26/01/2026